Nefopam-d3 (hydrochloride)

Nefopam-d3 (hydrochloride) is the deuterium labeled Nefopam hydrochloride. Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2].

Product Specifications

CAS Number

[1346603-30-2]

Product Name Alternative

Fenazoxine-d3 (hydrochloride)

UNSPSC

12352005

Target

β-catenin

Type

Isotope-Labeled Compounds

Related Pathways

Stem Cell/Wnt

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Purity

98.0

Solubility

10 mM in DMSO

Smiles

[2H]C(N1CCOC(C2=CC=CC=C2)C3=CC=CC=C3C1)([2H])[2H].[H]Cl

Molecular Formula

C17H17D3ClNO

Molecular Weight

292.82

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27 (2) :103-11.|[3]Poon R, et al. A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS One. 2012;7 (5) :e37940.|[4]Baht GS, et al. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone. 2017 May;98:31-36.